Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study

被引:0
作者
Hirokazu Kagawa
Fumihiko Urabe
Yuria Kiuchi
Kota Katsumi
Ryotaro Yamaguchi
Yushi Suhara
Kentaro Yoshihara
Yuma Goto
Ibuki Sadakane
Yuji Yata
Shun Saito
Shiro Kurawaki
Shino Ajisaka
Keiichiro Miyajima
Kazuhiro Takahashi
Kosuke Iwatani
Yu Imai
Keigo Sakanaka
Minoru Nakazono
Takashi Kurauchi
Sotaro Kayano
Hajime Onuma
Koichi Aikawa
Takafumi Yanagisawa
Kojiro Tashiro
Shunsuke Tsuzuki
Akira Furuta
Jun Miki
Takahiro Kimura
机构
[1] The Jikei University School of Medicine,Department of Urology
[2] Jikei University Kashiwa Hospital,Department of Urology
[3] Jikei Katsushika Medical Center,Department of Urology
来源
International Journal of Clinical Oncology | 2024年 / 29卷
关键词
Upper tract urothelial carcinoma; Neoadjuvant chemotherapy; Adjuvant candidate;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:55 / 63
页数:8
相关论文
共 31 条
[1]  
Redrow GP(2016)Upper tract urothelial carcinoma: epidemiology, high risk populations and detection Minerva Urol Nefrol 68 350-358
[2]  
Matin SF(2000)Upper tract urothelial neoplasms: incidence and survival during the last 2 decades J Urol 164 1523-1525
[3]  
Munoz JJ(2010)The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center Eur Urol 58 574-580
[4]  
Ellison LM(2012)Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature Eur Urol 62 100-114
[5]  
Favaretto RL(2020)Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Lancet 395 1268-1277
[6]  
Shariat SF(2021)Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma N Engl J Med 384 2102-2114
[7]  
Chade DC(2016)The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours Eur Urol 70 106-119
[8]  
Lughezzani G(1982)Evaluating the yield of medical tests JAMA 247 2543-2546
[9]  
Burger M(2021)Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial Lancet Oncol 22 525-537
[10]  
Margulis V(2022)The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis Urol Oncol 40 243-261